The man had recurrent melanoma that failed to respond to therapy or surgery when he enrolled in a clinical trial at the Fred Hutchinson Cancer Research Center in Seattle. The disease had spread to his lungs and a lymph node before he received the two-hour infusion of the lab-grown immune system cell